Cargando…

Combination therapy of midodrine and droxidopa for refractory hypotension in heart failure with preserved ejection fraction per a pharmacist’s proposal: a case report

BACKGROUND: Patients with chronic heart failure (CHF) are often treated using many diuretics for symptom relief; however, diuretic use may have to continue despite hypotension development in these patients. Here, we present a case of heart failure with preserved ejection fraction (HFpEF), which is d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asai, Yuki, Sato, Tomoaki, Kito, Daisuke, Yamamoto, Takanori, Hioki, Iwao, Urata, Yasuhisa, Abe, Yasuharu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927230/ https://www.ncbi.nlm.nih.gov/pubmed/33653416 http://dx.doi.org/10.1186/s40780-021-00193-z

Ejemplares similares

Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease
por: Kremens, Daniel, et al.
Publicado: (2017)

Midodrine for orthostatic hypotension
Publicado: (2020)

Neurogenic orthostatic hypotension – management update and role of droxidopa
por: Vijayan, Joy, et al.
Publicado: (2015)

Six‐Month Use of Droxidopa for Neurogenic Orthostatic Hypotension
por: François, Clément, et al.
Publicado: (2019)

Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension
por: Biaggioni, Italo, et al.
Publicado: (2017)

Use of droxidopa for the long-term treatment of neurogenic orthostatic hypotension
por: Raj, Satish R, et al.
Publicado: (2019)

Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension
Publicado: (2020)

Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension
por: Byun, Jung‐Ick, et al.
Publicado: (2019)

Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease
por: Goodman, Brent P., et al.
Publicado: (2017)

Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?
por: Kaufmann, Horacio
Publicado: (2017)

Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease
por: Claassen, Daniel, et al.
Publicado: (2017)

Droxidopa Persistence in Neurogenic Orthostatic Hypotension May Be Affected by Titration Approach
por: Amjad, Fahd, et al.
Publicado: (2021)

Ampreloxetine Versus Droxidopa in Neurogenic Orthostatic Hypotension: A Comparative Review
por: Hoxhaj, Pranvera, et al.
Publicado: (2023)

Midodrine to optimize heart failure therapy in patients with concurrent hypotension
por: Shiu, Paul, et al.
Publicado: (2022)

Neurogenic orthostatic hypotension in Parkinson’s disease: evaluation, management, and emerging role of droxidopa
por: Isaacson, Stuart H, et al.
Publicado: (2014)

Randomized Withdrawal Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension Responsive to Droxidopa
por: Biaggioni, Italo, et al.
Publicado: (2015)

Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension
por: François, Clément, et al.
Publicado: (2016)

Case report: severe myoclonus associated with oral midodrine treatment for hypotension
por: Ye, Xiaolan, et al.
Publicado: (2020)

Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report
por: Ho, Annie H., et al.
Publicado: (2020)

Droxidopa for neurogenic orthostatic hypotension: A randomized, placebo-controlled, phase 3 trial
por: Kaufmann, Horacio, et al.
Publicado: (2014)

Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension
por: Hauser, Robert A., et al.
Publicado: (2016)

2198 Cognitive and behavioral side effects in patients treated with droxidopa for neurogenic orthostatic hypotension
por: McDonell, Katherine, et al.
Publicado: (2018)

Management of Hypotension and Bradycardia Caused By Spinal Cord Injury. The Usefulness of Midodrine and Methylxanthines
por: Mojtahedzadeh, Mojtaba, et al.
Publicado: (2019)

Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
por: Gupta, Fiona, et al.
Publicado: (2017)

Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy
por: Goodman, Brent P., et al.
Publicado: (2017)

Managing neurogenic orthostatic hypotension with droxidopa in a patient with Parkinson disease, atrial fibrillation, and hypertension
por: Mehdirad, Ali, et al.
Publicado: (2017)

Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial)
por: Anstey, Matthew H., et al.
Publicado: (2017)

Midodrine efficacy
Publicado: (2021)

Erratum to: Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
por: Gupta, Fiona, et al.
Publicado: (2017)

Characterization of the changes in supine blood pressure with long‐term use of droxidopa in patients with neurogenic orthostatic hypotension
por: Hewitt, L. Arthur, et al.
Publicado: (2021)

Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment
por: Hauser, Robert A., et al.
Publicado: (2022)

Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus
por: Vernino, Steven, et al.
Publicado: (2017)

Managing supine hypertension in a patient with non-diabetic autonomic neuropathy receiving droxidopa for neurogenic orthostatic hypotension
por: Vernino, Steven, et al.
Publicado: (2017)

Fludrocortisone Is Associated With a Higher Risk of All‐Cause Hospitalizations Compared With Midodrine in Patients With Orthostatic Hypotension
por: Grijalva, Carlos G., et al.
Publicado: (2017)

Potential risks in using midodrine for persistent hypotension after cardiac surgery: a comparative cohort study
por: Tremblay, Jan-Alexis, et al.
Publicado: (2020)

Treatment via oral midodrine in a patient with prolonged hypotension following carotid artery stenting: a case report
por: Jenab, Yaser, et al.
Publicado: (2022)

Factors influencing the effectiveness of recombinant human soluble thrombomodulin on disseminated intravascular coagulation: a retrospective study
por: Asai, Yuki, et al.
Publicado: (2020)

Belly dancer syndrome improved by withdrawal of droxidopa and amantadine
por: Kaga, Mihiro, et al.
Publicado: (2023)

Treatment of Cirrhosis-Associated Hyponatremia with Midodrine and Octreotide
por: Patel, Sharad, et al.
Publicado: (2017)

Hemodynamic Effects of an Increased Midodrine Dosing Frequency
por: Macielak, Shea A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cavuq9kmopaf5maob17jc8cgid